参考文献
［1］ Redfield MM.Heart failure with preserved ejection fraction［J］.N Engl J Med，2016，375：1868-1877.
［2］ Dunlay SM，Roger VL，Redfield MM.Epidemiology of heart failure with preserved ejection fraction［J］.Nat Rev Cardiol，2017，14：591-600.
［3］ Nair N.Epidemiology and pathogenesis of heart failure with preserved ejection fraction［J］.Rev Cardiovasc Med，2020，21：531-540.
［4］ Pfeffer MA，Shah AM，Borlaug BA.Heart failure with preserved ejection fraction in perspective［J］.Circ Res，2019，124：1598-1617.
［5］ Shah KS，Xu H，Matsouaka RA，et al.Heart failure with preserved，borderline，and reduced ejection fraction：5-year outcomes［J］.J Am Coll Cardiol，2017，70：2476-248.
［6］ Tromp J，Teng TH，Tay WT，et al.Heart failure with preserved ejection fraction in Asia［J］.Eur J Heart Fail，2019，21：23-36.
［7］ Frisk M，Le C，Shen X，et al.Etiology-dependent impairment of diastolic cardiomyocyte calcium homeostasis in heart failure with preserved ejection fraction［J］.J Am Coll Cardiol，2021，77：405-419.
［8］ Simmonds SJ，Cuijpers I，Heymans S，et al.Cellular and molecular differences between HFpEFand HFrEF：A step ahead in an improved pathological understanding［J］.Cells，2020，9：242.
［9］ Frisk M，Le C，Shen X，et al.Etiology-dependent impairment of diastolic cardiomyocyte calcium homeostasis in heart failure with preserved ejection fraction［J］.J Am Coll Cardiol，2021，77：405-419.
［10］ Upadhya B，Kitzman DW.Heart failure with preserved ejection fraction：New approaches to diagnosis and management［J］.Clin Cardiol，2020，43：145-155.
［11］ Borlaug BA.Evaluation and management of heart failure with preserved ejection fraction［J］.Nat Rev Cardiol，2020，17：559-573.(https://www.daowen.com)
［12］ Gazewood JD，Turner PL.Heart failure with preserved ejection fraction：diagnosis and management［J］.Am Fam Physician，2017，96：582-588.
［13］ Reddy YNV，Carter RE，Obokata M，et al.A simple，evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction［J］.Circulation，2018，138：861-870.
［14］ Barandiarán Aizpurua A，Sanders-van Wijk S，Brunner-La Rocca HP，et al.Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction［J］.Eur J Heart Fail，2020，22：413-421.
［15］ Pieske B，Tschöpe C，de Boer RA，et al.How to diagnose heart failure with preserved ejection fraction：The HFA-PEFF diagnostic algorithm：A consensus recommendation from the Heart Failure Association（HFA）of the European Society of Cardiology（ESC）［J］.Euro Heart J，2019，40：3297-3317.
［16］ Solomon SD，Vaduganathan M，Claggett BL，et al.Sacubitril／valsartan across the spectrum of ejection fraction in heart failure［J］.Circulation，2019，141：352-361.
［17］ Seferovic JP，Claggett B，Seidelmann SB，et al.Effect of sacubitril／valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes：A post hoc analysis from the PARADIGM-HF trial［J］.Lancet Diabetes Endocrinol，2021，75：333-340.
［18］ Tridetti J，Nguyen，Trung ML，et al.The PARAGON-HF trial［J］.Rev Med Liege，2020，75：130-135.
［19］ Zheng SL，Chan FT，Nabeebaccus，et al.Drug treatment effects on outcomes in heart failure with preserved ejection fraction：A systematic review and meta-analysis［J］.Heart，2018，104：407-415.
［20］ Wintrich J，Kindermann I，Ukena C，et al.Therapeutic approaches in heart failure with preserved ejection fraction：Past，present，and future［J］.Clin Res in Cardiolo，2020，109：1079-1098.
［21］ Packer M，Kitzman DW.Obesity-related heart failure with a preserved ejection fraction：The mechanistic rationale for combining inhibitors of aldosterone，neprilysin，and sodium-glucose cotransporter-2［J］.JACC Heart Fail，2018，6：633-639.